+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Batten Disease Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Batten Disease Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Batten Disease Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 195 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6083644
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Batten Disease Market grew from USD 57.61 million in 2024 to USD 60.65 million in 2025. It is expected to continue growing at a CAGR of 5.23%, reaching USD 78.23 million by 2030.

Executive Summary Introduction: Understanding the Batten Disease Landscape

Batten disease, formally known as neuronal ceroid lipofuscinosis (NCL), represents a cluster of rare, inherited neurodegenerative disorders characterized by progressive vision loss, cognitive decline, seizures, and premature death. The infantile form of NCL typically manifests within the first year of life, often culminating in severe neurological impairment by age three. As the scientific community advances in molecular genetics, diagnostics, and therapeutic modalities, stakeholders across biopharma, research institutes, and care providers are poised to navigate a rapidly evolving landscape. This executive summary synthesizes the critical shifts in research, development, regulatory frameworks, and market access barriers shaping the Batten disease ecosystem. Drawing on the latest clinical trial data, policy developments, and supply chain analyses, it highlights the multidimensional challenges and opportunities inherent in addressing this devastating condition. Emphasizing collaboration between biotechnology innovators, hospitals, and patient advocacy groups, this report underscores the imperative for integrated strategies that accelerate diagnostic precision, optimize treatment pathways, and ensure equitable access to emerging therapies, thereby aligning scientific breakthroughs with the unmet needs of affected families.

Transformative Shifts Reshaping the Batten Disease Ecosystem

The Batten disease space has witnessed several transformative shifts, driven by breakthroughs in gene therapy vectors, enhanced diagnostic capabilities, and patient-centric care models. Notably, the advent of adeno-associated virus-based gene therapies has redefined early intervention paradigms, enabling targeted correction of pathogenic CLN gene variants. Concurrently, genetic testing platforms leveraging next-generation sequencing and MRI-based biomarkers have significantly reduced diagnostic latency. These innovations have been complemented by evolving regulatory pathways that now accommodate accelerated approval mechanisms for orphan indications. Patient advocacy networks have also matured, fostering real-world evidence collection and shaping clinical trial designs that prioritize quality-of-life endpoints. Furthermore, the rise of decentralized clinical trials has expanded access to investigational protocols by leveraging telehealth infrastructure and home-based monitoring. Taken together, these shifts are establishing a more agile ecosystem where research institutes collaborate seamlessly with contract research organizations and specialized clinics to translate benchside discoveries into bedside solutions with unprecedented speed and precision.

Impact of 2025 U.S. Tariffs on Batten Disease Supply Chains

In 2025, the implementation of new U.S. tariffs on imported biomanufacturing reagents, viral vectors, and specialized equipment has exerted cumulative pressure on the Batten disease value chain. Suppliers of enzyme replacement components and small molecule precursors have adjusted pricing structures to offset increased duties, resulting in elevated out-of-pocket costs for clinical and commercial programs. Consequently, biotechnology companies and contract research organizations have accelerated efforts to localize manufacturing, forge partnerships with domestic vendors, and leverage emerging free trade zones to mitigate cost escalation. Meanwhile, hospitals and rehabilitation centers are revising procurement strategies, exploring bulk purchasing agreements and distribution collaborations to preserve budgetary discipline. Although tariff-induced complexities have introduced short-term headwinds, they have also catalyzed strategic realignment across the industry, fostering supply chain resilience and incentivizing investment in regional production hubs.

Key Market Segmentation Insights for Batten Disease Therapeutics

Deep analysis across multiple axes reveals nuanced dynamics shaping the Batten disease therapeutic market. Based on disease type, the infantile subtype remains the primary focus for early-phase and pivotal studies. Based on treatment modality, antibiotic therapy’s role in secondary infection management coexists with enzyme replacement therapy efforts, while gene therapy emerges as a frontrunner alongside small molecule drugs and stem cell therapy innovations. Based on drug type, FDA-approved products are complemented by off-label regimens and an expanding pipeline of orphan drugs. Based on patient demographics, attention spans infants, newborns, and toddlers, yet preschool children and adolescents are increasingly included to capture broader neurological endpoints. Based on care setting, home care solutions integrate remote monitoring, while hospitals, rehabilitation centers, and specialized clinics deliver multidisciplinary support. Based on research & development stage, preclinical studies feed a robust Phase I pipeline that transitions into Phase II and III trials. Based on supportive therapies, occupational, physical, and speech therapy programs enhance quality-of-life measures. Based on diagnostic tools, EEGs, genetic testing, and MRIs underpin early detection protocols. Based on end-user, biotechnology companies, hospitals, and research institutes drive commercialization efforts. Based on market players, biotech companies, contract research organizations, and pharmaceutical companies collaborate across the value chain. Based on product type, biologics, biosimilars, and recombinant proteins diversify therapeutic portfolios. Based on distribution channels, hospital pharmacies, online pharmacies, and retail pharmacies optimize product reach. Based on awareness programs, healthcare provider training, media campaigns, and patient advocacy groups amplify disease education and early screening initiatives.

Key Regional Insights across Americas, EMEA, and Asia-Pacific

Regional dynamics in the Batten disease landscape reveal both commonalities and distinctive priorities across major territories. In the Americas, the robust presence of biotechnology companies and research institutes has fostered an environment conducive to pioneering gene therapy trials and early access programs. Meanwhile, regulatory harmonization between the United States and Canada facilitates cross-border collaboration in clinical research and compassionate use frameworks. In Europe, Middle East & Africa, a diversified payer mix and evolving orphan drug policies have prompted manufacturers to adopt flexible pricing models and risk-sharing agreements, particularly within national health systems that emphasize pharmacoeconomic evidence. Additionally, collaborative consortia spanning Western Europe and Northern Africa are driving pan-regional registries and natural history studies. Across Asia-Pacific, rapid expansion of specialized clinics and genetic testing infrastructure in key markets such as Japan, South Korea, and Australia is accelerating diagnostic uptake. Concurrently, local biotech ventures in India and China are forging partnerships with global pharmaceutical companies to co-develop novel therapies, underscoring the region’s growing influence in the Batten disease arena.

Key Company Insights in the Batten Disease Treatment Arena

Within the competitive landscape, certain organizations have emerged as innovation leaders and strategic collaborators in the Batten disease field. Abeona Therapeutics Inc. has advanced its CLN3 gene therapy candidate toward late-stage clinical evaluation, while Alexion Pharmaceuticals Inc. continues to refine enzyme replacement formulations targeting lysosomal pathways. Amicus Therapeutics has leveraged its chaperone platform to optimize small molecule stability, and BioMarin Pharmaceutical Inc. has sustained momentum in orphan drug approvals. Denali Therapeutics is pioneering blood-brain-barrier modulation strategies, whereas Neurogene Inc. is scaling vector manufacturing to support global expansion. Novartis AG’s broad portfolio includes both gene editing initiatives and recombinant protein therapeutics. Orchard Therapeutics has established precedent-setting market launches for hematopoietic stem cell interventions, and Passage Bio, Inc. is harnessing proprietary capsid engineering for tailored delivery. Regenxbio Inc. partners with academic centers to accelerate preclinical programs, and Teva Pharmaceuticals Industries Ltd. draws on its generics expertise to champion biosimilar access in emerging markets. Strategic alliances, licensing deals, and co-development agreements among these players reflect a collective commitment to diversify treatment options and optimize patient outcomes.

Actionable Recommendations for Industry Leaders

Industry leaders should consider the following actions to strengthen their strategic positioning and accelerate therapeutic advances. First, prioritize collaboration with genetic testing laboratories and neurodiagnostic experts to reduce time to diagnosis and expand patient registries. Second, diversify supply chains by engaging regional manufacturing partners and establishing contingency stocks to neutralize tariff-related disruptions. Third, invest in adaptive trial designs that incorporate real-world data and quality-of-life metrics, ensuring alignment with evolving regulatory expectations for orphan indications. Fourth, deepen engagement with advocacy groups and media campaigns to enhance disease awareness and support early intervention initiatives. Fifth, leverage distribution channel synergies by forging partnerships across hospital pharmacies, online platforms, and specialty clinics to streamline product access. Sixth, allocate resources to supportive therapy integration, embedding occupational, physical, and speech therapy into comprehensive care models. Finally, pursue strategic alliances and licensing agreements with leading biotechnology firms, contract research organizations, and pharmaceutical companies to share risk, pool expertise, and accelerate time to market.

Conclusion: Navigating the Future of Batten Disease Therapies

In summary, the Batten disease landscape is at a pivotal juncture marked by technological ingenuity, regulatory evolution, and heightened stakeholder collaboration. Transformative shifts in gene therapy, diagnostics, and data generation are converging to redefine therapeutic paradigms, while tariff pressures and regional variations underscore the importance of agile supply chain and market access strategies. By harnessing segmentation insights, regional dynamics, and competitive benchmarks, decision-makers can craft targeted initiatives that address unmet needs across disease subtypes, treatment modalities, and care settings. As the industry coalesces around shared objectives-accelerating innovation, optimizing patient outcomes, and ensuring equitable access-there is a clear path forward to translate scientific breakthroughs into tangible improvements in quality of life for children and families affected by Batten disease.

Market Segmentation & Coverage

This research report categorizes the Batten Disease Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Infantile NCL
  • Antibiotic Therapy
  • Enzyme Replacement Therapy
  • Gene Therapy
  • Small Molecule Drugs
  • Stem Cell Therapy
  • FDA Approved
  • Off-Label
  • Orphan Drugs
  • Adolescents
  • Infants
  • Newborns
  • Preschool Children
  • Toddlers
  • Home Care
  • Hospitals
  • Rehabilitation Centers
  • Specialized Clinics
  • Phase I Trials
  • Phase II Trials
  • Phase III Trials
  • Preclinical Studies
  • Occupational Therapy
  • Physical Therapy
  • Speech Therapy
  • EEGs
  • Genetic Testing
  • MRIs
  • Biotechnology Companies
  • Hospitals
  • Research Institutes
  • Biotech Companies
  • Contract Research Organizations
  • Pharmaceutical Companies
  • Biologics
  • Biosimilars
  • Recombinant Proteins
  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies
  • Healthcare Provider Training
  • Media Campaigns
  • Patient Advocacy Groups

This research report categorizes the Batten Disease Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Batten Disease Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Abeona Therapeutics Inc.
  • Alexion Pharmaceuticals Inc.
  • Amicus Therapeutics
  • BioMarin Pharmaceutical Inc.
  • Denali Therapeutics
  • Neurogene Inc.
  • Novartis AG
  • Orchard Therapeutics
  • Passage Bio, Inc.
  • Regenxbio Inc.
  • Teva Pharmaceuticals Industries Ltd.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Batten Disease Market, by Disease Type
8.1. Introduction
8.2. Infantile NCL
9. Batten Disease Market, by Treatment Modality
9.1. Introduction
9.2. Antibiotic Therapy
9.3. Enzyme Replacement Therapy
9.4. Gene Therapy
9.5. Small Molecule Drugs
9.6. Stem Cell Therapy
10. Batten Disease Market, by Drug Type
10.1. Introduction
10.2. FDA Approved
10.3. Off-Label
10.4. Orphan Drugs
11. Batten Disease Market, by Patient Demographics
11.1. Introduction
11.2. Adolescents
11.3. Infants
11.4. Newborns
11.5. Preschool Children
11.6. Toddlers
12. Batten Disease Market, by Care Setting
12.1. Introduction
12.2. Home Care
12.3. Hospitals
12.4. Rehabilitation Centers
12.5. Specialized Clinics
13. Batten Disease Market, by Research & Development Stage
13.1. Introduction
13.2. Phase I Trials
13.3. Phase II Trials
13.4. Phase III Trials
13.5. Preclinical Studies
14. Batten Disease Market, by Supportive Therapies
14.1. Introduction
14.2. Occupational Therapy
14.3. Physical Therapy
14.4. Speech Therapy
15. Batten Disease Market, by Diagnostic Tools
15.1. Introduction
15.2. EEGs
15.3. Genetic Testing
15.4. MRIs
16. Batten Disease Market, by End-User
16.1. Introduction
16.2. Biotechnology Companies
16.3. Hospitals
16.4. Research Institutes
17. Batten Disease Market, by Market Players
17.1. Introduction
17.2. Biotech Companies
17.3. Contract Research Organizations
17.4. Pharmaceutical Companies
18. Batten Disease Market, by Product Type
18.1. Introduction
18.2. Biologics
18.3. Biosimilars
18.4. Recombinant Proteins
19. Batten Disease Market, by Distribution Channels
19.1. Introduction
19.2. Hospital Pharmacies
19.3. Online Pharmacies
19.4. Retail Pharmacies
20. Batten Disease Market, by Awareness Programs
20.1. Introduction
20.2. Healthcare Provider Training
20.3. Media Campaigns
20.4. Patient Advocacy Groups
21. Americas Batten Disease Market
21.1. Introduction
21.2. Argentina
21.3. Brazil
21.4. Canada
21.5. Mexico
21.6. United States
22. Asia-Pacific Batten Disease Market
22.1. Introduction
22.2. Australia
22.3. China
22.4. India
22.5. Indonesia
22.6. Japan
22.7. Malaysia
22.8. Philippines
22.9. Singapore
22.10. South Korea
22.11. Taiwan
22.12. Thailand
22.13. Vietnam
23. Europe, Middle East & Africa Batten Disease Market
23.1. Introduction
23.2. Denmark
23.3. Egypt
23.4. Finland
23.5. France
23.6. Germany
23.7. Israel
23.8. Italy
23.9. Netherlands
23.10. Nigeria
23.11. Norway
23.12. Poland
23.13. Qatar
23.14. Russia
23.15. Saudi Arabia
23.16. South Africa
23.17. Spain
23.18. Sweden
23.19. Switzerland
23.20. Turkey
23.21. United Arab Emirates
23.22. United Kingdom
24. Competitive Landscape
24.1. Market Share Analysis, 2024
24.2. FPNV Positioning Matrix, 2024
24.3. Competitive Analysis
24.3.1. Abeona Therapeutics Inc.
24.3.2. Alexion Pharmaceuticals Inc.
24.3.3. Amicus Therapeutics
24.3.4. BioMarin Pharmaceutical Inc.
24.3.5. Denali Therapeutics
24.3.6. Neurogene Inc.
24.3.7. Novartis AG
24.3.8. Orchard Therapeutics
24.3.9. Passage Bio, Inc.
24.3.10. Regenxbio Inc.
24.3.11. Teva Pharmaceuticals Industries Ltd.
25. ResearchAI
26. ResearchStatistics
27. ResearchContacts
28. ResearchArticles
29. Appendix
List of Figures
FIGURE 1. BATTEN DISEASE MARKET MULTI-CURRENCY
FIGURE 2. BATTEN DISEASE MARKET MULTI-LANGUAGE
FIGURE 3. BATTEN DISEASE MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL BATTEN DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL BATTEN DISEASE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2030 (%)
FIGURE 10. GLOBAL BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 14. GLOBAL BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. GLOBAL BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2024 VS 2030 (%)
FIGURE 16. GLOBAL BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. GLOBAL BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2024 VS 2030 (%)
FIGURE 18. GLOBAL BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. GLOBAL BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2024 VS 2030 (%)
FIGURE 20. GLOBAL BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. GLOBAL BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2024 VS 2030 (%)
FIGURE 22. GLOBAL BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
FIGURE 24. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 25. GLOBAL BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2024 VS 2030 (%)
FIGURE 26. GLOBAL BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 27. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 28. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 29. GLOBAL BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2030 (%)
FIGURE 30. GLOBAL BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 31. GLOBAL BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2024 VS 2030 (%)
FIGURE 32. GLOBAL BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 33. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 34. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 35. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 36. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 37. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 38. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 39. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 40. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 41. BATTEN DISEASE MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 42. BATTEN DISEASE MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. BATTEN DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL BATTEN DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL BATTEN DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL BATTEN DISEASE MARKET SIZE, BY INFANTILE NCL, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL BATTEN DISEASE MARKET SIZE, BY ANTIBIOTIC THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL BATTEN DISEASE MARKET SIZE, BY ENZYME REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL BATTEN DISEASE MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL BATTEN DISEASE MARKET SIZE, BY SMALL MOLECULE DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL BATTEN DISEASE MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL BATTEN DISEASE MARKET SIZE, BY FDA APPROVED, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL BATTEN DISEASE MARKET SIZE, BY OFF-LABEL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL BATTEN DISEASE MARKET SIZE, BY ORPHAN DRUGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL BATTEN DISEASE MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL BATTEN DISEASE MARKET SIZE, BY INFANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL BATTEN DISEASE MARKET SIZE, BY NEWBORNS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRESCHOOL CHILDREN, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL BATTEN DISEASE MARKET SIZE, BY TODDLERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL BATTEN DISEASE MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL BATTEN DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL BATTEN DISEASE MARKET SIZE, BY REHABILITATION CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL BATTEN DISEASE MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL BATTEN DISEASE MARKET SIZE, BY PHASE I TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL BATTEN DISEASE MARKET SIZE, BY PHASE II TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL BATTEN DISEASE MARKET SIZE, BY PHASE III TRIALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRECLINICAL STUDIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL BATTEN DISEASE MARKET SIZE, BY OCCUPATIONAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL BATTEN DISEASE MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL BATTEN DISEASE MARKET SIZE, BY SPEECH THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL BATTEN DISEASE MARKET SIZE, BY EEGS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL BATTEN DISEASE MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL BATTEN DISEASE MARKET SIZE, BY MRIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL BATTEN DISEASE MARKET SIZE, BY BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL BATTEN DISEASE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL BATTEN DISEASE MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL BATTEN DISEASE MARKET SIZE, BY BIOTECH COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL BATTEN DISEASE MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL BATTEN DISEASE MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL BATTEN DISEASE MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 52. GLOBAL BATTEN DISEASE MARKET SIZE, BY BIOSIMILARS, BY REGION, 2018-2030 (USD MILLION)
TABLE 53. GLOBAL BATTEN DISEASE MARKET SIZE, BY RECOMBINANT PROTEINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 54. GLOBAL BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 55. GLOBAL BATTEN DISEASE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 56. GLOBAL BATTEN DISEASE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 57. GLOBAL BATTEN DISEASE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 58. GLOBAL BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 59. GLOBAL BATTEN DISEASE MARKET SIZE, BY HEALTHCARE PROVIDER TRAINING, BY REGION, 2018-2030 (USD MILLION)
TABLE 60. GLOBAL BATTEN DISEASE MARKET SIZE, BY MEDIA CAMPAIGNS, BY REGION, 2018-2030 (USD MILLION)
TABLE 61. GLOBAL BATTEN DISEASE MARKET SIZE, BY PATIENT ADVOCACY GROUPS, BY REGION, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 65. AMERICAS BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 66. AMERICAS BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 67. AMERICAS BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 68. AMERICAS BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 69. AMERICAS BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 70. AMERICAS BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 71. AMERICAS BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 72. AMERICAS BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 73. AMERICAS BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 74. AMERICAS BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 75. AMERICAS BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 77. ARGENTINA BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 78. ARGENTINA BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 79. ARGENTINA BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 80. ARGENTINA BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 81. ARGENTINA BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 82. ARGENTINA BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 83. ARGENTINA BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 84. ARGENTINA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 85. ARGENTINA BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 86. ARGENTINA BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 87. ARGENTINA BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 88. ARGENTINA BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 89. BRAZIL BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 90. BRAZIL BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 91. BRAZIL BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 92. BRAZIL BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 93. BRAZIL BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 94. BRAZIL BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 95. BRAZIL BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 96. BRAZIL BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 97. BRAZIL BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. BRAZIL BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 99. BRAZIL BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 100. BRAZIL BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 101. BRAZIL BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 102. CANADA BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 103. CANADA BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 104. CANADA BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 105. CANADA BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 106. CANADA BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 107. CANADA BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 108. CANADA BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 109. CANADA BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 110. CANADA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 111. CANADA BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 112. CANADA BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 113. CANADA BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 114. CANADA BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 115. MEXICO BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 116. MEXICO BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 117. MEXICO BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 118. MEXICO BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 119. MEXICO BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 120. MEXICO BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 121. MEXICO BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 122. MEXICO BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 123. MEXICO BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 124. MEXICO BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 125. MEXICO BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 126. MEXICO BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 127. MEXICO BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 128. UNITED STATES BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 129. UNITED STATES BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 130. UNITED STATES BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 131. UNITED STATES BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 132. UNITED STATES BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 133. UNITED STATES BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 134. UNITED STATES BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 135. UNITED STATES BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 136. UNITED STATES BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. UNITED STATES BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 138. UNITED STATES BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 139. UNITED STATES BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 140. UNITED STATES BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 141. UNITED STATES BATTEN DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 142. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 143. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 144. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 145. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 146. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 147. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 148. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 149. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 150. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 151. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 152. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 153. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 154. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 155. ASIA-PACIFIC BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 156. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 157. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 158. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 159. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 160. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 161. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 162. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 163. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 164. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 165. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 166. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 167. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 168. AUSTRALIA BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 169. CHINA BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 170. CHINA BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 171. CHINA BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 172. CHINA BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 173. CHINA BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 174. CHINA BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 175. CHINA BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 176. CHINA BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 177. CHINA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 178. CHINA BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 179. CHINA BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 180. CHINA BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 181. CHINA BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 182. INDIA BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 183. INDIA BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 184. INDIA BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 185. INDIA BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 186. INDIA BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 187. INDIA BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 188. INDIA BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 189. INDIA BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 190. INDIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 191. INDIA BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 192. INDIA BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 193. INDIA BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 194. INDIA BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 195. INDONESIA BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 196. INDONESIA BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 197. INDONESIA BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 198. INDONESIA BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 199. INDONESIA BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 200. INDONESIA BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 201. INDONESIA BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 202. INDONESIA BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 203. INDONESIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. INDONESIA BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 205. INDONESIA BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 206. INDONESIA BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 207. INDONESIA BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 208. JAPAN BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 209. JAPAN BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 210. JAPAN BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 211. JAPAN BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 212. JAPAN BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 213. JAPAN BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 214. JAPAN BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 215. JAPAN BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 216. JAPAN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 217. JAPAN BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 218. JAPAN BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 219. JAPAN BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 220. JAPAN BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 221. MALAYSIA BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 222. MALAYSIA BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 223. MALAYSIA BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 224. MALAYSIA BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 225. MALAYSIA BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 226. MALAYSIA BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 227. MALAYSIA BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 228. MALAYSIA BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 229. MALAYSIA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 230. MALAYSIA BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 231. MALAYSIA BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 232. MALAYSIA BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 233. MALAYSIA BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 234. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 235. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 236. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 237. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 238. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 239. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 240. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 241. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 242. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 243. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 244. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 245. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 246. PHILIPPINES BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 247. SINGAPORE BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 248. SINGAPORE BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 249. SINGAPORE BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 250. SINGAPORE BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 251. SINGAPORE BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 252. SINGAPORE BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 253. SINGAPORE BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 254. SINGAPORE BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 255. SINGAPORE BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 256. SINGAPORE BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 257. SINGAPORE BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 258. SINGAPORE BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 259. SINGAPORE BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 260. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 261. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 262. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 263. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 264. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 265. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 273. TAIWAN BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 274. TAIWAN BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 275. TAIWAN BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 276. TAIWAN BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 277. TAIWAN BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 278. TAIWAN BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 279. TAIWAN BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 280. TAIWAN BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 281. TAIWAN BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 282. TAIWAN BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 283. TAIWAN BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 284. TAIWAN BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 285. TAIWAN BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 286. THAILAND BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 287. THAILAND BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 288. THAILAND BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 289. THAILAND BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 290. THAILAND BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 291. THAILAND BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 292. THAILAND BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 293. THAILAND BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 294. THAILAND BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 295. THAILAND BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 296. THAILAND BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 297. THAILAND BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 298. THAILAND BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 299. VIETNAM BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 300. VIETNAM BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 301. VIETNAM BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 302. VIETNAM BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 303. VIETNAM BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 304. VIETNAM BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 305. VIETNAM BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 306. VIETNAM BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 307. VIETNAM BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 308. VIETNAM BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 309. VIETNAM BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 310. VIETNAM BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 311. VIETNAM BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 312. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 313. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 314. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 315. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 316. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 317. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 318. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 319. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 320. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 321. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 322. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 323. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 324. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 325. EUROPE, MIDDLE EAST & AFRICA BATTEN DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 326. DENMARK BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 327. DENMARK BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 328. DENMARK BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 329. DENMARK BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 330. DENMARK BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 331. DENMARK BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 332. DENMARK BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 333. DENMARK BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 334. DENMARK BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 335. DENMARK BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 336. DENMARK BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
TABLE 337. DENMARK BATTEN DISEASE MARKET SIZE, BY DISTRIBUTION CHANNELS, 2018-2030 (USD MILLION)
TABLE 338. DENMARK BATTEN DISEASE MARKET SIZE, BY AWARENESS PROGRAMS, 2018-2030 (USD MILLION)
TABLE 339. EGYPT BATTEN DISEASE MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
TABLE 340. EGYPT BATTEN DISEASE MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
TABLE 341. EGYPT BATTEN DISEASE MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
TABLE 342. EGYPT BATTEN DISEASE MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 343. EGYPT BATTEN DISEASE MARKET SIZE, BY CARE SETTING, 2018-2030 (USD MILLION)
TABLE 344. EGYPT BATTEN DISEASE MARKET SIZE, BY RESEARCH & DEVELOPMENT STAGE, 2018-2030 (USD MILLION)
TABLE 345. EGYPT BATTEN DISEASE MARKET SIZE, BY SUPPORTIVE THERAPIES, 2018-2030 (USD MILLION)
TABLE 346. EGYPT BATTEN DISEASE MARKET SIZE, BY DIAGNOSTIC TOOLS, 2018-2030 (USD MILLION)
TABLE 347. EGYPT BATTEN DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 348. EGYPT BATTEN DISEASE MARKET SIZE, BY MARKET PLAYERS, 2018-2030 (USD MILLION)
TABLE 349. EGYPT BATTEN DISEASE MARKET SIZE, BY PRODUCT TYPE, 2018-

Companies Mentioned

  • Abeona Therapeutics Inc.
  • Alexion Pharmaceuticals Inc.
  • Amicus Therapeutics
  • BioMarin Pharmaceutical Inc.
  • Denali Therapeutics
  • Neurogene Inc.
  • Novartis AG
  • Orchard Therapeutics
  • Passage Bio, Inc.
  • Regenxbio Inc.
  • Teva Pharmaceuticals Industries Ltd.

Methodology

Loading
LOADING...

Related Topics

Related Reports

Batten Disease Market by Product, Type of Disease, Route of Administration, End-User - Global Forecast 2025-2030 - Product Image

Batten Disease Market by Product, Type of Disease, Route of Administration, End-User - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
Batten Disease - Pipeline Insight, 2025 - Product Image

Batten Disease - Pipeline Insight, 2025

  • Drug Pipelines
  • 60 Pages
  • Global
From
Drugs for Niemann-Pick Disease Type C Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Drugs for Niemann-Pick Disease Type C Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 182 Pages
  • Global, United States Global, United States
From
Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Type, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Transthyretin Amyloidosis Treatment Market Size, Share & Trends Analysis Report By Therapy, By Type, By Disease, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Therapy, By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030 - Product Image

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Therapy, By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.